Barclays
GLUE icon

Barclays’s Monte Rosa Therapeutics GLUE Stock Holding History

Barclays’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$341K Sell
28,575
-5,892
-17% -$101K ﹤0.01% 3679
2026
Q2 		$834K Buy
34,467
+23,114
+204% +$437K ﹤0.01% 2897
2026
Q1 		$187K Sell
11,353
-124,631
-92% -$2.38M ﹤0.01% 3725
2025
Q4 		$2.13M Buy
135,984
+63,029
+86% +$849K ﹤0.01% 2881
2025
Q3 		$541K Sell
72,955
-12,757
-15% -$67.6K ﹤0.01% 3764
2025
Q2 		$387K Buy
85,712
+39,502
+85% +$176K ﹤0.01% 3904
2025
Q1 		$214K Sell
46,210
-24,531
-35% -$150K ﹤0.01% 4002
2024
Q4 		$491K Buy
70,741
+16,233
+30% +$122K ﹤0.01% 3837
2024
Q3 		$289K Buy
54,508
+43,499
+395% +$220K ﹤0.01% 4109
2024
Q2 		$41.2K Sell
11,009
-10,739
-49% -$54.8K ﹤0.01% 4284
2024
Q1 		$153K Sell
21,748
-39,520
-65% -$234K ﹤0.01% 4245
2023
Q4 		$346K Buy
61,268
+48,097
+365% +$189K ﹤0.01% 4117
2023
Q3 		$63.1K Sell
13,171
-464
-3% -$2.99K ﹤0.01% 3768
2023
Q2 		$93.4K Sell
13,635
-1,534
-10% -$9.9K ﹤0.01% 3588
2023
Q1 		$118K Buy
15,169
+7,181
+90% +$49.9K ﹤0.01% 4091
2022
Q4 		$60.8K Buy
7,988
+6,772
+557% +$56.4K ﹤0.01% 4469
2022
Q3 		$10K Sell
1,216
-224
-16% -$2.06K ﹤0.01% 4298
2022
Q2 		$14K Sell
1,440
-7,668
-84% -$77K ﹤0.01% 4517
2022
Q1 		$128K Buy
+9,108
New +$126K ﹤0.01% 3676

Other funds holding GLUE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's GLUE Position: Q3 2026 in Review

Barclays reduced its Monte Rosa Therapeutics (GLUE) stake by 17% in Q3 2026, selling an estimated $101K and leaving 28,575 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

Barclays first reported a position in GLUE in Q1 2022 and has held it in 19 quarters since. The position peaked at $2.13M in Q4 2025. 52 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Barclays held 28,575 shares of Monte Rosa Therapeutics worth $341K as of Q3 2026.
  • Barclays sold 5,892 Monte Rosa Therapeutics shares in Q3 2026, an estimated $101K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3679 holding.
  • Barclays first reported a position in Monte Rosa Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Monte Rosa Therapeutics position peaked at $2.13M in Q4 2025.
  • 52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.